Daniel L V Bader
Overview
Explore the profile of Daniel L V Bader including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
86
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pratap P, Cottrell C, Quinn J, Carnathan D, Bader D, Tran A, et al.
bioRxiv
. 2024 Dec;
PMID: 39651156
During infection, the fusion peptide (FP) of HIV envelope glycoprotein (Env) serves a central role in viral fusion with the host cell. As such, the FP is highly conserved and...
2.
Cottrell C, Hu X, Lee J, Skog P, Luo S, Flynn C, et al.
Sci Transl Med
. 2024 May;
16(748):eadn0223.
PMID: 38753806
A protective HIV vaccine will likely need to induce broadly neutralizing antibodies (bnAbs). Vaccination with the germline-targeting immunogen eOD-GT8 60mer adjuvanted with AS01 was found to induce VRC01-class bnAb precursors...
3.
deCamp A, Corcoran M, Fulp W, Willis J, Cottrell C, Bader D, et al.
NPJ Vaccines
. 2024 Mar;
9(1):58.
PMID: 38467663
Vaccine priming immunogens that activate germline precursors for broadly neutralizing antibodies (bnAbs) have promise for development of precision vaccines against major human pathogens. In a clinical trial of the eOD-GT8...
4.
deCamp A, Corcoran M, Fulp W, Willis J, Cottrell C, Bader D, et al.
medRxiv
. 2023 Mar;
PMID: 36993183
One-sentence Summary: Human genetic variation can modulate the strength of vaccine-induced broadly neutralizing antibody precursor B cell responses.
5.
Matabaro E, Kaspar H, Dahlin P, Bader D, Murar C, Staubli F, et al.
Sci Rep
. 2022 Oct;
12(1):17021.
PMID: 36220874
No abstract available.
6.
Schorcht A, Cottrell C, Pugach P, Ringe R, Han A, Allen J, et al.
J Virol
. 2021 Oct;
96(1):e0155221.
PMID: 34669426
The human immunodeficiency virus type 1 (HIV-1) trimeric envelope glycoprotein (Env) is heavily glycosylated, creating a dense glycan shield that protects the underlying peptidic surface from antibody recognition. The absence...
7.
Matabaro E, Kaspar H, Dahlin P, Bader D, Murar C, Staubli F, et al.
Sci Rep
. 2021 Jun;
11(1):12656.
PMID: 34112888
No abstract available.
8.
Matabaro E, Kaspar H, Dahlin P, Bader D, Murar C, Staubli F, et al.
Sci Rep
. 2021 Feb;
11(1):3541.
PMID: 33574430
Backbone N-methylation and macrocyclization improve the pharmacological properties of peptides by enhancing their proteolytic stability, membrane permeability and target selectivity. Borosins are backbone N-methylated peptide macrocycles derived from a precursor...
9.
Brauer D, Hartman E, Bader D, Merz Z, Tullman-Ercek D, Francis M
J Am Chem Soc
. 2019 Feb;
141(9):3875-3884.
PMID: 30730722
Site-specific protein modification is a widely used strategy to attach drugs, imaging agents, or other useful small molecules to protein carriers. N-terminal modification is particularly useful as a high-yielding, site-selective...
10.
Maza J, Bader D, Xiao L, Marmelstein A, Brauer D, ElSohly A, et al.
J Am Chem Soc
. 2019 Feb;
141(9):3885-3892.
PMID: 30726077
A convenient enzymatic strategy is reported for the modification of proline residues in the N-terminal positions of proteins. Using a tyrosinase enzyme isolated from Agaricus bisporus (abTYR), phenols and catechols...